Skip to NavigationSkip to content

Business Services

Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board

Published on: 04/02/21

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has appointed Professor Mark Wilcox to its Scientific Advisory Board (SAB).

Raremark appoints Caroline O’Connor as CCO

Published on: 04/02/21

Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer.

Previously holding the position of Raremark’s Senior Vice President of Business Development, O’Connor will now take ownership of the company’s commercial focus and play a key role in growing its presence in the pharma industry.

Prior to joining the company, O’Connor’s focus was on eClinical technology, combined with establishing value and driving revenue growth from real-world evidence and digital patient support programmes in the post-approval setting.

Scenic Biotech appoints Dr Philippe Dro as Chairman

Published on: 02/02/21

Scenic Biotech has announced the appointment of Dr Philippe Dro as its independent Chairman. Dr Dro replaces Dr Ulrich Grau, who retires from the Board of Directors.

Swiss-based Dr Dro is trained in industrial pharmacy and finance. He has built a successful career in the European biotech and medtech sectors, serving on the boards of several start-ups and scaleups, initiating and executing notable strategic transactions. Alongside his role as Chairman of Scenic, he also serves as Chairman of Luciole Medical.

How COVID-19 has affected the oncology drugs market

Published on 25/01/21 at 04:01pm

In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the cancer drugs market – but not every change has necessarily been for the worse. Darcy Jimenez explores how the difficulties caused by the coronavirus crisis could improve drugs research, and speaks to major players about how they’ve adapted during this time

Raremark appoints Nicki Grundy as CFO

Published on: 20/01/21

Raremark, a global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer.

As a key member of Raremark’s senior leadership team, Grundy will take the lead on the company’s financial vision, strategic financial planning, and compliance.

Grundy has over 20 years of experience driving growth in businesses including CrownBio, Exco InTouch, and most recently Peppermint Technology, a legal software company.

Purespring Therapeutics to appoint Richard Francis as CEO

Published on: 11/01/21

Purespring Therapeutics, a kidney-focused AAV gene therapy company, has announced it will appoint Richard Francis as Chief Executive Officer from February this year.

Clinigen appoints Sam Herbert as Chief Operating Officer

Published on: 05/01/21

Clinigen, the global pharmaceutical and services company, has appointed Sam Herbert as Chief Operating Officer with immediate effect.

PureTech appoints George Farmer as Chief Financial Officer

Published on: 05/01/21

PureTech Health, a clinical-stage biotherapeutics company focused on highly differentiated medicines for devastating diseases, has appointed Dr George Farmer as its Chief Financial Officer.

As a key member of PureTech’s senior leadership team, Farmer will be responsible for all aspects of the company’s finances, including capital markets strategy and execution, strategic and financial planning, and financial reporting.

Novavax appoints Rick Crowley as Executive Vice President, Chief Operations Officer.

Published on: 22/12/20

Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has announced the appointment of Rick Crowley to the newly created position of Executive Vice President, Chief Operations Officer.

In this role, Crowley will have leadership responsibility for all operations, including Quality, Manufacturing, Supply Chain and Regulatory Affairs. He takes over manufacturing from Ben Machielse, who will continue with the company as an Executive Advisor to the Chief Executive Officer, supporting the development of the COVID-19 vaccine.

The importance of ethics and patient centricity in managed and early access programmes

Published on 21/12/20 at 05:30pm

Matt Fellows explores how early and managed access schemes are mutually beneficial to sponsors and patients alike, as well as how to ensure they can be as effective as possible in a rapidly changing world.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches